期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms23063041
关键词
antibody-drug conjugate; radiation therapy; therapeutic target; radiation-inducible
资金
- Medical Guidance Systems LLC, St. Louis, Missouri, USA
- NIH [R44CA210687, R41CA233020]
- Elsa U. Pardee Foundation [K22CA234404]
Therapeutic antibodies are effective in treating advanced-stage cancer by activating T-lymphocytes and targeting cancer-specific antigens. Additionally, using radiation therapy can enhance the efficacy of these antibodies and antibody-drug conjugates in cancer treatment.
Therapeutic antibodies used to treat cancer are effective in patients with advanced-stage disease. For example, antibodies that activate T-lymphocytes improve survival in many cancer subtypes. In addition, antibody-drug conjugates effectively target cytotoxic agents that are specific to cancer. This review discusses radiation-inducible antigens, which are stress-regulated proteins that are over-expressed in cancer. These inducible cell surface proteins become accessible to antibody binding during the cellular response to genotoxic stress. The lead antigens are induced in all histologic subtypes and nearly all advanced-stage cancers, but show little to no expression in normal tissues. Inducible antigens are exploited by using therapeutic antibodies that bind specifically to these stress-regulated proteins. Antibodies that bind to the inducible antigens GRP78 and TIP1 enhance the efficacy of radiotherapy in preclinical cancer models. The conjugation of cytotoxic drugs to the antibodies further improves cancer response. This review focuses on the use of radiotherapy to control the cancer-specific binding of therapeutic antibodies and antibody-drug conjugates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据